Is there a prostate-specific antigen upper limit for radical prostatectomy?

BJU International

Volumn 108, Issue 7, 2011, Pages 1093-1100

  Gontero, Paulo ^a   Spahn, Martin ^b   Tombal, Bertrand ^c   Bader, Pia ^d   Hsu, Chao Yu ^e   Marchioro, Giansilvio ^f   Frea, Bruno ^g   Van Der Eeckt, Kathy ^e   Kneitz, Burkhard ^b   Frohneberg, Detlef ^d   Tizzani, Alessandro ^a   Van Poppel, Hendrik ^e   Joniau, Steven ^e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d General Hospital Karlsruhe   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g UNIVERSITY OF UDINE   (Italy)

Author keywords

prostate cancer; prostate specific antigen; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; TREATMENT PLANNING;

AGED; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80052791663     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10076.x     Document Type: Article

References (18)

1. O'Brien MF, Cronin AM, Fearn PA, et al,. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 3591-7
2. Makarov DV, Trock BJ, Humphreys EB, et al,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101 (Pubitemid 46891611)
3. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH,. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72 (Pubitemid 46606365)
4. Yossepowitch O, Eggener SE, Bianco FJ Jr, et al,. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007; 178: 493-9 (Pubitemid 47030486)
5. Zwergel U, Suttmann H, Schroeder T, et al,. Outcome of prostate cancer patients with initial PSA ≥20 ng/mL undergoing radical prostatectomy. Eur Urol 2007; 52: 1058-66 (Pubitemid 47337032)
6. Gallina A, Jeldres C, Chun FK, et al,. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol 2007; 52: 1374-80 (Pubitemid 47445969)
7. Rana A, Karamanis K, Lucas MG, Chisholm GD,. Identification of metastatic disease by T category, gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992; 69: 277-81
8. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H,. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-51 (Pubitemid 26081236)
9. Inman BA, Davies JD, Rangel LJ, et al,. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer 2008; 113: 1544-51
10. Spahn M, Joniau S, Gontero P, et al,. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/mL: a European multi-institutional study of 712 patients. Eur Urol 2010; 58: 1-7
11. Steuber T, Erbersdobler A, Graefen M, et al,. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy. Cancer 2006; 106: 775-82 (Pubitemid 43238443)
12. 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287-97 (Pubitemid 46780894)
13. Lecouvet FE, Geukens D, Stainier A, et al,. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25: 3281-7 (Pubitemid 47325613)
14. Swanson G, Thompson I, Basler J, Crawford ED,. Metastatic prostate cancer-does treatment of the primary tumor matter. J Urol 2006; 176: 1292-8 (Pubitemid 44307237)
15. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247-52 (Pubitemid 27138705)
16. Crook J, Malone S, Perry G, et al,. Postradiotherapy prostate biopsies: what do they really mean? Results from 498 patients. Int J Radiat Oncol Biol Phys 2000; 48: 355-67
17. Bolla M, Collette L, Blank L, et al,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
18. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)